tbuckley/cabot-search huggingface dataset:
CAT RINGWORM.
Authors: M. SYDNEY THOMSON
Journal: British Journal of Dermatology (1925)

Journal Article CAT RINGWORM. Get access M. SYDNEY THOMSON, M.A., M.D., M.R.C.P. M. SYDNEY THOMSON, M.A., M.D., M.R.C.P. Physician for Diseases of the Skin to the Belgrave Hospital for Children Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology and Syphilis, Volume 37, Issue 6, 1 June 1925, Pages 269–270, https://doi.org/10.1111/j.1365-2133.1925.tb09959.x Published: 01 June 1925
Metabolomics approaches to identify biomarkers of non-alcoholic fatty liver disease
Authors: Aidan McGlinchey, Dawei Geng, Olivier Govaere, Vlad Ratziu, Elisabetta Bugianesi, Jörn M. Schattenberg, Ann K Daly, Tuulia Hyötyläinen, Quentin Anstee, Matej Orešič
Journal: Journal of Hepatology (2020)
What's new in the other general journals
Authors: Christopher Martyn
Journal: BMJ (2005)

There's something of an industry among evidence based medicine experts in devising ways to present to practising clinicians numerical information on the performance of diagnostic tests. How useful they are in everyday practice is another matter. In a randomised experiment at a continuing medical education conference, 183 physicians were asked to estimate probabilities of common illnesses from vignettes of six patients. Each vignette described the symptoms and risk profile of the patient and contained the result of a commonly used diagnostic test. The accuracy of the test was described either in terms of sensitivity and specificity or as a likelihood ratio or as a simple graphic representation of the likelihood ratio. Participating doctors were randomly allocated to receive one of these descriptions. Differences in estimates of the probability of disease between the groups assigned to different presentations were very small after the test. The authors admit that their findings are preliminary but think that presenting test performance as a likelihood ratio does not have much influence on the way doctors interpret the results. Another possibility, of course, is that clinicians are so familiar with the business of applying the results of diagnostic tests to patient management that they simply do not need these heuristics. Annals of Internal Medicine2005;143:184-9 [OpenUrl][1][PubMed][2][Web of Science][3] People with end stage renal disease may receive treatment with either peritoneal dialysis or haemodialysis. Which is better? In the absence of data from randomised controlled trials, we cannot know for sure, but follow-up of a large group of such patients found that mortality was higher in those receiving peritoneal dialysis, although the difference became statistically significant only during the second year of treatment. More than 1000 patients at 81 centres in 19 states of the United States took part. A quarter of the patients receiving peritoneal dialysis and 5% of those receiving haemodialysis switched methods … [1]: {openurl}?query=rft.jtitle%253DAnnals%2Bof%2BInternal%2BMedicine%26rft.stitle%253DANN%2BINTERN%2BMED%26rft.issn%253D0003-4819%26rft.aulast%253DPuhan%26rft.auinit1%253DM.%2BA.%26rft.volume%253D143%26rft.issue%253D3%26rft.spage%253D184%26rft.epage%253D189%26rft.atitle%253DA%2BRandomized%2BTrial%2Bof%2BWays%2BTo%2BDescribe%2BTest%2BAccuracy%253A%2BThe%2BEffect%2Bon%2BPhysicians%2527%2BPost-Test%2BProbability%2BEstimates%26rft_id%253Dinfo%253Apmid%252F16061916%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [2]: /lookup/external-ref?access_num=16061916&link_type=MED&atom=%2Fbmj%2F331%2F7513%2F369.atom [3]: /lookup/external-ref?access_num=000230953900003&link_type=ISI
NHS distribution of funds unfair.
Authors: E. S. Williams, C. Scott, R. Brazil
Journal: BMJ (1992)

clinical departments, which facilitates the transfer of the system to other departments.We have also found that the information required by clinicians is greater than that required by management.From this basis an information strategy that takes into account the needs of all users-managers, nurses, clinicians, and administrative staff-is being developed for the trust.
Randomised trial of steroid therapy in acute liver failure. Report from the European Association for the Study of the Liver (EASL).
Journal: Gut (1979)

A randomised, un-blinded clinical trial of hydrocortisate treatment in acute liver failure was carried out by 17 European centres. During a four year period 40 patients entered the study, 26 in the steroid group and 14 in the control group. The groups were found to be comparable, and the survival was 12 and 14%, respectively. A number of clinical and laboratory data, particularly HBsAg-positivity, appeared to carry some prognostic information, irrespective of treatment, but statistical significance was not achieved. Pooling of the present results with those from relevant published reports indicates a significant negative effect of steroid treatment in acute liver failure (P less than 0.2).
Implications of Regional Differences in Spending
Authors: Elliott S. Fisher, Dan Gottlieb, David Wennberg
Journal: Annals of Internal Medicine (2004)

Letters20 January 2004Implications of Regional Differences in SpendingElliott S. Fisher, MD, MPH, Dan Gottlieb, MS, and David Wennberg, MD, MPHElliott S. Fisher, MD, MPHSearch for more papers by this author, Dan Gottlieb, MSSearch for more papers by this author, and David Wennberg, MD, MPHSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-140-2-200401200-00025 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Drs. Mueller and Kisloff raise questions about the causes of regional variations in spending and intensity. Regional differences in lack of health insurance and consequent differences in illness burden at age 65 years cannot explain the differences in spending and intensity observed in our study because we grouped regions according to differences in spending that were independent of regional differences in health status. Dr. Kisloff interprets our study as an attack on academic medical centers and technological advances. On the contrary, our study shows that low-spending regions provide just as much of the proven technologically advanced care (such ...References1. Fisher ES, Wennberg JE, Stukel TA, Sharp SM. Hospital readmission rates for cohorts of Medicare beneficiaries in Boston and New Haven. N Engl J Med. 1994;331:989-95. [PMID: 8084356] CrossrefMedlineGoogle Scholar2. Wennberg JE, Fisher ES, Skinner JS. Geography and the debate over Medicare reform. Health Aff (Millwood). 2002;Supp Web Exclusives:W96-114. [PMID: 12703563] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Elliott S. Fisher, MD, MPH; Dan Gottlieb, MS; David Wennberg, MD, MPHAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoThe Implications of Regional Variations in Medicare Spending. Part 1: The Content, Quality, and Accessibility of Care Elliott S. Fisher , David E. Wennberg , Thrse A. Stukel , Daniel J. Gottlieb , F. L. Lucas , and Étoile L. Pinder Implications of Regional Differences in Spending Rudolph J. Mueller Implications of Regional Differences in Spending Barry Kisloff Implications of Regional Differences in Spending Howard A. Levin Implications of Regional Differences in Spending Rudy Fernandes Implications of Regional Differences in Spending George L. Weber Implications of Regional Differences in Spending Hyman Gaylis Implications of Regional Differences in Spending Franklin Gaylis Metrics Cited byThe Pragmatist's Guide to Comparative Effectiveness Research 20 January 2004Volume 140, Issue 2Page: 148-149KeywordsDatabasesDrugsElderlyHealth insuranceHip fracturesIntensive care unitsMyocardial infarctionOrthopedicsPatientsPercutaneous coronary intervention ePublished: 20 January 2004 Issue Published: 20 January 2004 Copyright & PermissionsCopyright © 2004 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Migraine Symptoms
Authors: Neill F. David
Journal: JAMA (1976)

<h3>To the Editor.—</h3> My most recently delivered copy of<i>JAMA</i>(May 3, 1976) contains an editorial in which one of my letters was "paraphrased" (235: 2006). Someone—the paraphraser, the copy editor, the printer, the proofreader(?)—goofed. In describing my first attack of migraine, I wrote that the visual scotoma was<i>most</i>disturbing (emphasis added). The editorial states that the scotoma was<i>not</i>disturbing (emphasis added). If you are going to print or paraphrase letters I write, don't change facts!
Neurobiology
Authors: Charles M. Poser
Journal: JAMA (1983)

The field of neurobiology is new only in the sense that it has emerged during recent years as an attempt to integrate, collate, and compare our knowledge of the nervous systems of vertebrates and invertebrates into some kind of coherent canvas. Because of the many complexities of these systems and the fact that so many disciplines, ranging from anatomy to enzyme histochemistry and synaptic physiology, have contributed to our understanding of function, it takes someone with vast erudition and almost foolhardy courage to undertake what this book's purpose is stated to be: "to summarize modern knowledge about nerve cells and their organization into functional circuits, and show how this relates to animal behavior." This goal has been achieved with a degree of success, lucidity, and almost Spartan restraint, unusual in such texts. The book's organization lends itself particularly well to use as a textbook or ancillary reference for courses in
Abstract 160: Angiography Based Comparison of Echocardiography Z-value Equations for the Case Definition of Coronary Artery Dilatation Following Kawasaki Disease
Authors: Nagib Dahdah, Frederick Trinh Tan, Chantale Lapierre, Joaquim Miro, Anne Fournier
Journal: Circulation (2015)

Introduction: Echo-based coronary artery (CA) Z-value is the current standard for the case definition of CA dilatation (Z&gt;2.5) in KD. Extrapolating Z-value equations to selective angiography has not been evaluated. CA to aortic valve (AV) ratio is stable versus BSA (Figure). Methods: CA measurements from selective angiography were compared to echo measurements within 3 months interval, late after KD. Measurements were performed 3-5 mm from CA ostium for patients without aneurysms, and proximal to the aneurysm for the remainder. The AV was measured in the echo long axis and the angio frontal views. Z-values and CA/AV ratios were compared between angio and echo measurements. Results: There were 22 cases with and 55 without CA sequelae. Echo measurements overestimated the smallest CA segments (intercept 0.75 mm), with an error attenuation for larger coronaries (slope 0.74, r 2 0.45). In contrast, CA/AV ratio had a better correlation for all CA size range (intercept 0.04, slope 0.87, r2 0.55). There was a disagreement between echo and angio for the case definition of coronary dilatation for the Z-value equations (p value 0.02 and 0.04), but not for the CA/AV ratio (p value 0.1 and 0.27). The best sensitivity and specificity of echo to predict angio-based CA status were obtained with the CA/AV (100 and 93 percent for the right and 50 and 87 percent for the left coronary, versus 36 and 93 percent and 44 and 87 percent, respectively). Conclusion: CA/AV is a better representative of the angiographic CA status compared to echocardiography based Z-value calculations.
Diagnostic Radiology
Authors: Harold G. Jacobson
Journal: JAMA (1980)

In the past several years, advances in diagnostic radiology have added new dimensions to this discipline. In the main, they involve computerized tomography (CT), ultrasonography, radionuclide scanning (all either completely or relatively noninvasive), and interventional radiology, eg, angioplasty. The number and scope of these innovative developments, leading to significant improvement in diagnostic accuracy and, therefore, in patient care, transcend the availability of space in this presentation. Thus, a brief discussion of the more important developments and their clinical applications follows. <h3>CT of the Head and Spine</h3> Computerized tomographic scanning continues to make significant strides technically, particularly with innovative modifications of software. Through improved handling and digitizing of the accumulated data, CT scans and roentgenograms of the skull and spine may be obtained simultaneously in cases of trauma to these areas, without moving the patient. The cursor then may be used to identify the segments to be scanned, increasing accuracy, reducing
Affiliation agreements between the University and the Community Hospital
Authors: R. E. Mack
Journal: JAMA (1974)

AS MEDICAL schools have expanded their enrollment in the last decade with the coincident decline of the usefulness of public hospitals for medical education, there has been a considerable increase in university-community hospital affiliations. Although a number of problems have been encountered in these arrangements, the major difficulty is a failure of the affiliating institutions to identify clearly their objectives. The most important objective of the university seeking community hospital affiliation is an expansion of its educational capability without having to develop or build additional hospital facilities. The community hospital's major objective should relate to a strengthening of the quality of its medical services, which it anticipates will result from the university presence. Inevitably, there are secondary objectives for the university, for the hospital, and for the participating physicians, which may be important when one attempts to define a workable relationship.<sup>1</sup>Since these secondary objectives may be in conflict,
IS EXERCISE UNHEALTHY?
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Propranolol infusions after abdominal surgery
Authors: C. C. Hug
Journal: JAMA (1983)

<h3>To the Editor.—</h3> We refer to the article entitled "Continuous Propranolol Infusion Following Abdominal Surgery" by Smulyan et al (1982; 247:2539). For the past three years, we have been infusing propranolol hydrochloride in patients unable to take oral drugs after coronary artery bypass surgery.<sup>1,2</sup>We have the following comments and suggestions regarding this mode of propranolol administration. Infusion rates of 2 to 3 mg/hr usually produce levels within the therapeutic range within the first three hours, but if the levels are too low or reached too slowly, it is better to give one or more intravenous (IV) bolus doses (1 mg each) than to increase the infusion rate, a practice well illustrated in the clinical use of lidocaine hydrochloride infusions (<i>JAMA</i>1976;236:273). Given an average elimination halftime of approximately four hours in normal subjects,<sup>3</sup>steady-state levels of propranolol will not be achieved until the infusion has continued at
Surgical treatment of extracranial arterial occlusion
Journal: JAMA (1971)

<h3>To the Editor.—</h3> The Joint Study of Extracranial Arterial Occlusion (<b>211</b>:1993, 1970) provided valuable data comparing the results of carotid surgical and nonsurgical treatment of extracranial arterial insufficiency in patients without neurological deficits in the three following groups: (1) unilateral carotid stenosis (2) bilateral carotid stenosis and (3) carotid occlusion plus contralateral stenosis. However there is doubt in my mind that the most important data were analyzed in determining the best method of treatment. The authors have decided to compare the value of treatments on the basis of transient attacks in the patients who survive the original hospitalization and surgery. In their analysis surgery is a better therapy in subgroups two and three. Several objections can be offered. First the analysis does not evaluate those who have been injured or have died as a result of the original therapy. Second it evaluates data which are the least important and
'Back to moon, on to Mars' becomes space medicine's 1990s rallying cry
Authors: J. Smith
Journal: JAMA (1990)

THE FINAL DECADE of the 20th century and the first quarter of the 21st century are likely to be critical for the United States' space program and its medical aspects. To maintain US preeminence in space research, the 1988 national space policy of (then) President Reagan reaffirmed the need for initiatives such as a permanently staffed space station. Now, at the request of President Bush, the National Space Council (which is headed by Vice President Quayle) is pondering a National Aeronautics and Space Administration (NASA) study that calls for such a space station in the 1990s as the first step in a multiphase effort that has important implications for space medicine. This late 20th century space station would be followed by a return—this time for much longer stays—to the moon by humans early in the 21st century. After that would come the long-discussed manned mission to Mars. In accordance with
Today's drugs. Nalidixic acid.
Journal: BMJ (1967)

With the help of expert contributors we publish below notes on a selection of drugs in current use. Nalidixic AcidThis drug is marketed by the Bayer Products Company under the name Negram. Chemistry and PharmacologyNalidixic acid is a naphthyridine derivative.1 It is soluble in dilute alkali, and will withstand sterilization by autoclaving without decomposition.The drug is active against most Gram-
Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality
Authors: Ewa Gogola, Alexandra A. Duarte, Julian R. de Ruiter, Wouter W. Wiegant, Jonas A. Schmid, Roebi de Bruijn, Dominic I. James, Sergi Guerrero Llobet, Daniel J. Vis, Stefano Annunziato, Bram van den Broek, Marco Barazas, Ariena Kersbergen, Marieke van de Ven, Madalena Tarsounas, Donald J. Ogilvie, Marcel van Vugt, Lodewyk F.A. Wessels, Jirina Bartkova, Irina Gromova, Miguel Andújar-Sánchez, Jiri Bartek, Massimo Lopes, Haico van Attikum, Piet Borst, Jos Jonkers, Sven Rottenberg
Journal: Cancer Cell (2019)
Preimplantation Testing to Produce an HLA-Matched Donor Infant—Reply
Authors: Norman C. Fost
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 658: Antiproliferative effects of type II diabetes agents in Fanconi derived oral squamous carcinoma
Authors: Kim Miller, Beverly Wuertz, David Potter, Frank G. Ondrey
Journal: Cancer Research (2019)

Abstract Fanconi anemia is a rare disease characterized by bone marrow failure requiring transplantation at a young age. Patients with Fanconi Anemia are at risk for the development of squamous cell carcinomas of the skin and mucosal surfaces at risks several hundred fold higher than control populations and these malignancies can pursue an aggressive, often fatal, course. Our group has been interested in repurposing Type 2 diabetes agents for oral cancer prevention and treatment. Presently, we examined the effects of the thiazolidinedione drug, pioglitazone, and an experimental biguanide, N1-hexyl-N5-benzyl-biguanide (HBB), on the proliferation of Fanconi-derived oral carcinoma cells. We incubated MOP FA1,a, VU-1131, and VU-1365 b, and C squamous cell carcinoma cell lines with vehicle controls or the thiazolidinedione pioglitazone or biguanide (HBB). We found dose-dependent decreases in cellular proliferation in all three Fanconi-derived cell lines at physiologically relevant concentrations (10 - 50 µM) after 1 to 3 days in several experiments. The effects were not due to simple cytotoxicity as judged by trypan blue staining. In other non-squamous cell lines of cervical and oral cavity origins we have previously discovered similar effects. These agents affect PPAR gamma associated pathways (pioglitazone) or mTOR and mitochondrial glucose metaboliscm pathways (HBB). Since Fanconi anemia patients are highly susceptible to DNA damaging effects of cytotoxic chemotherapy, these classes of agents might be attractive in Fanconi Anemia oral cancer treatment or prevention. Metformin, another biguanide, is currently postulated to delay bone marrow failure in the Fanconi population and is currently in use in an early phase clinical trial. Our results may, therefore, be attratciveattractive for oral cancer prevention and treatment in this population, as they are well tolerated. Further examination of molecular mechanisms will likely generate putative pharmacodynamics markers for future clinical trials. Citation Format: Kim Miller, Beverly Wuertz, David Potter, Frank G. Ondrey. Antiproliferative effects of type II diabetes agents in Fanconi derived oral squamous carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 658.